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Summary--LNCaP cells contain androgen receptors with a mutation in the steroid binding 
domain (Thr 868 changed to Ala) resulting in a changed hormone specificity. Both the 
wild-type and mutated androgen receptors were transfected into COS cells. Transcription 
activation was studied in cells co-transfected with an androgen sensitive reporter (CAT) gene. 
The wild-type androgen receptor was activated by the agonist R1881, but the antiandrogens 
did not enhance transcription apart from a partial agonistic effect at high concentrations of 
cyproterone acetate. The mutated androgen receptor was fully activated by R1881, 
cyproterone acetate and hydroxyflutamide, but not by ICI 176,334. Receptor transformation 
to a tight nuclear binding state was studied by preparation of detergent washed nuclei and 
Western blotting with a specific antibody against he androgen receptor. Nuclei of COS cells 
transfected with wild-type receptor retained the receptor when the cells had been treated with 
the agonist R1881, partially retained receptors when treated with antiandrogen cyproterone 
acetate, but did not retain receptor when treated with hydroxyflutamide or ICI 176,334. The 
cells transfected with the mutated receptor additionally retained nuclear receptors after 
treatment with hydroxyflutamide. Weconclude that each one of the three antiandrogens tested 
displayed ifferent characteristics with respect to its effect on transformation a d transcription 
activation. 
INTRODUCTION 
Effects of androgens in target cells are mediated 
by binding to the androgen receptor. After 
binding of the hormone the receptor is trans- 
formed to a DNA-binding form with a high 
affinity for hormone response lements of target 
genes. Subsequently, the transcription of these 
genes is modulated by binding of the trans- 
formed steroid-receptor complex and inter- 
action with other transcription factors. The 
specificity of hormonal action is accomplished 
both by the specific recognition of the target 
genes and by the specificity of the hor- 
mone-receptor interaction, determined by the 
steroid binding part of the receptor [1, 2]. 
Antiandrogens act by inhibition of the bind- 
ing of androgens to the receptor [3-5], but their 
precise molecular mechanisms of action are at 
present not known. Several mechanisms have 
been proposed for the mechanism of action of 
steroid-receptor antagonists, ranging from in- 
*To whom correspondence should be addressed. 
duction of an abnormal conformation of the 
receptor, impaired translocation of the receptor 
to the nucleus, impaired dissociation of the 
heteromeric receptor complex, impaired 
receptor dimerization and binding of the 
receptor to DNA, to impaired interaction of 
the DNA-bound receptor with transcription 
factors [6-12]. 
In the present study we have compared the 
androgen receptor from LNCaP tumor cells and 
the normal, wild-type receptor with respect o 
antiandrogen mechanism of action. LNCaP 
cells are derived from a metastatic lesion of a 
human prostatic arcinoma, contain androgen 
receptors and respond to androgens with 
growth in cell culture [13]. In these cells increase 
in growth rate is also observed in the presence 
of low doses of estrogens and progestagens, 
despite the absence of estrogen or progestagen 
receptors, shown previously with specific anti- 
bodies against these receptor proteins [14]. In 
addition, several, but not all, antiandrogens 
stimulate growth of these cells. These effects are 
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due to a mutation in the ligand binding domain 
of the androgen receptor of LNCaP cells: amino 
acid 868 (Thr) is replaced by Ala [15]. 
In previous studies with LNCaP cells we 
could correlate transcription activation with 
heat-shock protein dissociation and nuclear e- 
tention of receptors [16]. To study nuclear eten- 
tion and transcription activation under identical 
conditions for both the mutated LNCaP and the 
wild-type receptor, these receptors were trans- 
fected into the same type of cells. We thus 
obtained COS cells containing either type of 
receptor and could eliminate cell-type specific 
effects. The results show receptor-type specific 
effects of the different antiandrogens, both with 




[3H]R1881, (87Ci/mmol) and unlabelled 
R1881 (methyltrienolone) were purchased fron 
NEN (Boston, MA); butyryl-CoA from Sigma 
(St Louis, MO). Cyproterone acetate was a gift 
from Schering (Berlin, Germany), hydroxyflu- 
tamide from Schering, USA (Bloomfield, N J), 
ICI 176,334 (trade mark 'Casodex') from IC1 
Pharmaceuticals (Macclesfield, Cheshire, Eng- 
land). All other steroids were purchased from 
Steraloids (Wilton, NH). ['4C]chloramphenicol 
(50-60 mCi/mmol) was obtained from 
Amersham (UK). The glucocorticoid/ 
progestagen/androgen r sponsive CAT con- 
struct pG29GtkCAT[17] was generously pro- 
vided by Dr R. Renkawitz. 
Transfections 
Construction of expression vectors (pAR0 for 
wild-type, pARL for LNCaP mutant androgen 
receptor) and culture of COS-I cells was as 
described previously [15]. 
For transcription regulation studies COS-1 
cells were transfected by the calcium-phosphate 
precipitation method; 5 x 105 cells/dish (30 cm 2) 
were transfected with either 2.5pg pAR0 or 
2.5#g pARL and 2.5pg pG29GtkCAT re- 
porter gene. Carrier DNA (pTZ) was added to 
a total of 10 #g per dish. After 1 day the cells 
were exposed to 15% glycerol for 1.5 min and 
washed twice. Thereafter culture medium with 
different compounds at the indicated concen- 
trations was added and culture was continued 
for 1 day. 
For nuclear retention studies COS-I cells 
were transfected by electroporation (Bio-Rad 
Gene Pulser). Cells obtained from stock cultures 
(60× 106cells) were resuspended in 3200#1 
phosphate buffered saline (PBS) containing ei- 
ther pAR0 or pARL (equal amounts of either 
plasmid; 1 to 10 pg/ml, depending on the batch 
of COS cells used) and divided over 4 electropo- 
ration-cuvettes (width 0.4cm). After 10rain 
at room temperature the cells were exposed to 
a single voltage pulse (200V, 960/~F), and 
allowed to remain in the buffer for 10min. 
Finally the cells were pooled and equal amounts 
plated out in 12 culture fasks at a density of 
5 × 106cells/150cm 2 and cultured for 2 days. 
CA T assays 
After culture in experimental media the cells 
were harvested for CAT (chloramphenicol 
acetyltransferase) assay, performed essentially 
as described previously [15, 18]. Reaction mix- 
ture (20pl) was mixed with 7 M urea (5ml), 
scintillation fluid (10 ml) added, and '4C activity 
estimated. For each compound (or combination 
of compounds) tested, the amount of CAT 
activity after subtraction of background activity 
(vehicle only; 0.2% ethanol), was expressed as 
percentage of the highest level of CAT activity 
that was found for cells incubated with R1881. 
Background activity was <5% of the highest 
levels of CAT activity (at 10 ,0 to 10 9M 
R1881). Experiments were performed in tripli- 
cate. 
Incubation, subcellular f actionation and Western 
blot analysis 
Two days after transfection equal amounts of 
cells, obtained from one batch of transfected 
cells, were washed and incubated in serum-flee 
minimum essential medium (MEM) with differ- 
ent compounds for 1 h at 37°C. Subsequently, 
the cells were washed and scraped in ice cold 
buffer A [sodium phosphate 10mM, EDTA 
1.5 mM, l=t-thioglycerol 12 mM, dithiothreitol 
(DTT) 10raM, PMSF 0.6mM, leupeptin 
0.25 mM, bacitracin 0.5 mM and glycerol 10%, 
v/v; pH 7.4]. The cells were then lysed by 3 times 
freeze-thawing (freezing in liquid nitrogen, 
thawing at 10°C) and centrifuged for 10min. 
The crude nuclear (800g) pellet was resuspended 
in buffer A with 0.2% (v/v) Triton X-100. After 
5 rain the nuclei were pelleted and washed with 
buffer A. Nuclear extracts were made by incu- 
bating the nuclei with extraction buffer 
(0.5 ml/flask; Tris-HC1 40 raM, EDTA 1.5 mM, 
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DTT 10mM, PMSF 0.6mM, leupeptin 
0.25 mM, bacitracin 0.5 mM, NaCI 0.5 M and 
glycerol 10%, v/v; pH 8.5) for 1 h at 4°C. After 
centrifugation for 30 min, 105,000g at 4°C, the 
supernatant was used for receptor immunopre- 
cipitation and Western blot analysis as de- 
scribed previously [19]. In brief, the monoclonal 
antibody F39.4.1 directed against amino acids 
301-320 in the N-terminal domain of the andro- 
gen receptor [20] was chemically cross-linked 
directly to protein-A-Sepharose and used for 
immuno-purification f receptors. SDS-PAGE 
was carried out and after electrophoresis, the 
slab gel was subjected to Western blotting. Blots 
were incubated with antibody F39.4.1 and the 
antibodies were visualized with a chemilumines- 
cence detection procedure. Densitometric s ans 
of the blots were performed (Bio-Rad Video 
Densitometer). 
RESULTS 
Reporter gene activation 
The expression vector for either the wild-type 
or the mutated androgen receptor from LNCaP 
cells was co-transfected together with an andro- 
gen responsive reporter gene into COS-I cells 
and the differences in effects on transcription of
antiandrogens were investigated. The relative 
binding affinities of antiandrogens for the an- 
drogen receptor are only a few percent of those 
for androgens, therefore higher amounts of the 
antiandrogens had to be added than of the 
androgen R1881 [4, 15, 16]. The results in Fig. l 
show that R1881 could induce CAT activity in 
cells with the wild-type receptor. Of the antian- 
drogens only cyproterone acetate induced CAT 
activity at elevated concentrations. R1881 and 
cyproterone acetate also bind to progesterone 
receptors. The reporter gene contains a GRE 
(pG29G-tk-CAT, [17]) and would be responsive 
to the progestagenic a tivities of R1881 and 
cyproterone acetate in addition to their 
(anti)androgenic a tivities, if progesterone r - 
ceptors were present. However, the COS cells 
did not contain progesterone r ceptors and no 
CAT activity was induced by progestagens in 
the absence of the androgen receptor vectors. 
When the mutant receptors were expressed in
COS cells, CAT activity was fully induced by 
the antiandrogens hydroxyflutamide and 
cyproterone acetate, but not by ICI 176,334 
(Fig. 1). Induction of CAT activity with 
cyproterone acetate was even higher than with 
R1881. In competition studies (Fig. 2) hydrox- 
yflutamide and ICI 176,334 could suppress 
R1881 effects in cells with wild-type receptor, 
whereas cyproterone acetate suppressed activity 
to approx. 50%. Only ICI 176,334 suppressed 
the effect of R1881 on CAT activity in the cells 
with mutant receptor, indicating that this com- 
pound remained antagonistic in the presence of 
the mutated receptor. 
Androgen receptor in nuclear extracts 
Receptors were isolated from nuclei of COS 
cells after transfection either with the wild-type 
receptor or mutated androgen receptor and 
incubation with R1881 or antiandrogens. The 
presence of receptors in nuclear extracts is in- 
dicative for the transformation process of the 
steroid-receptor complex to a tight nuclear 
binding form in a complex with DNA [1, 2]. 
Figure 3 shows that extracts from cells with 
wild-type receptor contained appreciable 
amounts of receptors after incubation with 
R1881, a still detectable amount after incu- 
bation with cyproterone acetate, but hardly any 
receptor after incubation with the other two 
antiandrogens. Cells with the mutated receptor 
additionally retained receptors after incubation 
with hydroxyflutamide. In both cells with wild- 
type or mutated receptor incubation with ICI 
176,334 did not result in the presence of nuclear 
receptors, in addition this compound could pre- 
vent the uptake of receptors when added to- 
gether with R1881 (data not shown). 
DISCUSSION 
Transcription activation by steroid receptors 
has been shown to be cell type and promoter 
context specific. Variable activation of a steroid 
independent transcription activation function, 
present in the N-terminal region of steroid 
receptors is probably involved in cell specific 
partial agonistic effects of some antagonists of 
steroid hormones [5, 7, 19]. The partial agonist 
activity of the antiprogestagen RU 38.486 in 
some cells has been explained by such a mechan- 
ism[10,22]. It could be envisaged that cell 
specific protein factors influence this effect. In 
LNCaP cells several antiandrogens show agon- 
istic properties. To exclude any cell specific 
property apart from an effect of the mutated 
androgen receptor, we transfected both wild- 
type and mutated receptor into COS cells and 
studied transformation a d transcription acti- 
vation under comparable conditions. 
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Fig. 1. Transcription activation. Induction of CAT activity in COS cells transfected with plasmids 
containing either the wild-type androgen receptor or the androgen receptor from LNCaP cells and 
co-transfected with an androgen sensitive reporter gene. Cells were incubated with different compounds: 
R1881, hydroxyflutamide (HF), ICI 176,334 (ICI) and cyproterone acetate (CPA). Activity is expressed 
in % of the activity found for 1 nM R1881 (set at 100%). - -  : not determined. 
The single mutation in the steroid binding 
domain of the mutated androgen receptor pro- 
foundly affected nuclear retention and tran- 
scription activation i  COS cells for several, but 
not all antiandrogens. The antagonistic effect of 
ICI 176,334 was not influenced by the mutation; 
this compound was shown to inhibit transform- 
ation to a tight nuclear bound state and to 
inhibit gene transcription induced by andro- 
gens. In a previous study [16] we could show 
that in the intact LNCaP cells ICI 176,334 also 
prevented the heat-shock protein dissociation 
step in the process of androgen receptor acti- 
vation preceding tight nuclear binding. Studies 
on heat-shock protein interaction could not be 
included in the present study: due to high 
intercellular variation in the levels of expression 
of the androgen receptors after transient trans- 
fection, several side-effects were observed (e.g. 
presence of non-ligand binding forms of recep- 
tors). At a lower mean expression level reliable 
results could be obtained, but the limited sensi- 
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Fig. 2. Effects of antagonists on androgen induced transcrip- 
tion. COS cells were transfected with different plasmids as 
described in the legend of Fig. 1 and incubated both with 
0.1 nM R1881 and a series of concentrations of different 
antagonists. Activity is expressed in % of the activity found 
for0.1 nM R1881 (C; control incubation, without antagon- 
ist). (A), HF, hydroxyflutamide; (O), ICI, ICI 176,334; 
(B), CPA, cyproterone acetate. 
tivity of the available antibodies did not permit 
estimation of heat-shock protein dissociation i
COS cells. 
Progestagen and estrogen antagonists have 
been tentatively divided into two types depend- 
ing on their level of action. One type would 
interfere with dimerization and subsequent 
binding to DNA. The other type of antihor- 
mones would induce DNA-binding of the re- 
ceptor, but act by blocking the transcription 
activation function localized in the C-terminal 
steroid binding domain of the recep- 
tor [10, 21-23]. In the present study each one of 
the three antiandrogens tested isplayed iffer- 
ent characteristics with respect o its effect on 
transformation and transcription activation 
(summarized in Table 1). Both hydroxy- 
flutamide and ICI 176,334 prevented formation 
in COS cells of a tight nuclear binding form of 
the wild-type receptor. However, a subtle 
change induced by a point mutation in the 
ligand binding domain of the LNCaP receptor 
did convert hydroxyflutamide, but not ICI 
176,334 to a full agonist. Cyproterone acetate 
could convert some wild-type receptors to the 
tight nuclear bound form and showed partial 
agonism. Agonistic effects of cyproterone acet- 
ate were also previously observed in studies on 
androgen receptors transfected into CV-1 
cells [24], the cell-type of which COS cells were 
derived. This partial agonistic effect is a cell 
specific effect, in HeLa cells transfected with 
the wild-type receptor hardly any agonistic 
effect of cyproterone acetate was observed [15]. 
Cyproterone acetate was a full agonist for the 
mutated receptor, both in HeLa and in COS 
cells. 
l oo  
t3 
Wild-type 
R1881 HF ICI CPA 
Mutant 




Fig. 3. Immunochemical detection of androgen receptors innuclear extracts. COS-cells obtained from one 
batch of transfected cells, were incubated with different compounds and androgen receptors were isolated 
from nuclei. Either 1 nM R1881 or 5 gM of the antagonists hydroxyflutamide (HF); ICI 176,334 (ICI) 
or cyproterone acetate (CPA) were added. (C; control incubation without added compounds). The figure 
shows both an example of the immunoblot and results of densitometric s ans (intensity of R1881 set at 
100%). Error bars indicate SD of 3 experiments. 
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Table 1. Summary of the effects of antagonists on the wild-type and mutated receptors 
Transcription Nuclear etention 
activation (COS cells) (COS cells) 
Growth of LNCaP 
cells Wild-type Mutant Wild-type Mutant 
HF + + - + 
ICI . . . .  
CPA + + / - + + / - + 
- : no effect; + / - : limited effect; + : full effect. HF: hydroxyflutamide; ICl: ICI 176,334; 
CPA: cyproterone acetate. 
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